[Perspectives in immunotherapy of malignant tumors].
The paper summarizes the perspectives of experimental tumour immunotherapy with immunomodulatory cytokines; it points out that some polypeptidic cytokines, which can be prepared with recombinant DNA technology and display immunoregulatory properties, seem to be suitable for treatment of human cancer. In conclusion, two recent trends of experimental tumour immunotherapy are being stressed: Chemoimmunotherapy using the combination of some cytostatics and interleukin 2, and combination setting of those lymphokines which were shown to be efficient as single agent in controlled clinical trials, such as interleukin 2, alpha interferon and tumour necrosis factor.